sarret joseph j  insider stock trading  openinsider sector all sectors group by sector aerospace agriculture automobile building business services chemical electrical energy fashion financial food  beverage fund healthcare household insurance machinery media metals mining other personal services real estate retail technology telecom transportation utility industry all industries group by industry insiders filings all purchases sales cik   address co corium international inc  constitution drive menlo park ca   results links secyahoogooglefinviztradingviewstockchartsstocktwitsdownload csv tc stat stk ins fil d w m q h y avg pretpwins filing date t date ticker issuerinc sector indindustry owner ost rel title t tval price l qty oc own h ry ry rm rm rw rw rd rd fd fw fm fm fm fy  coricorium international incdehealthdrugpharmaceutical preparationssarret joseph jcaochief busd  coricorium international incdehealthdrugpharmaceutical preparationssarret joseph jcaochief bumdd  cdxscodexis incchemochmindustrial organic chemicalssarret joseph jcaocbop phpd dderivative transaction in filing usually option exercise mmultiple transactions in filing earliest reported transaction date and weighted average transaction price aamended filing eerror detected in filing s  salesale of securities on an exchange or to another person s  saleoesale of securities on an exchange or to another person after option exercise f  taxpayment of exercise price or tax liability using portion of securities received from the company p  purchasepurchase of securities on an exchange or from another person return to top contact copyright   openinsidercom all rights reserved joseph sarret  codexis inc  zoominfocom   joseph j sarret md jd joins corium as chief business officer  thestreet action alerts plus access aapjim cramers best stocks for charitable trust portfoliomost recent trade alert investing rules trading commandments real money access rm rules of investingjim cramers best stocks for  commandmentsstressed out stockscramers blog cramer mad money etfs futures markets much more banksbiotechretailtechpersonal financeretirementfinancial advisor centerhow to spendoptionsfixed incomevideo privacy policyterms of use  thestreet inc all rights reserved djia nasdaq sp  market data updated sign in your memberships your account account preferences alerts newsletters subscribe logout subscribe access insights and guidance from our wall street pros find the product thats right for you action alerts plus action alerts options daily swing trade income seeker quant ratings real money real money pro stocks under  top stocks trifecta stocks real money pro portfolio chairmans club compare all chatter on the street joseph j sarret md jd joins corium as chief business officer globenewswire apr    am edt menlo park calif april   globe newswire  corium international inc nasdaqcori a commercialstage biopharmaceutical company focused on the development manufacture and commercialization of specialty transdermal products today announced that joseph j sarret md jd has joined the company in the newly created position of chief business officer reporting to coriums president and chief executive officer peter d staple dr sarret will serve as a member of the companys executive leadership team with responsibility for developing and implementing coriums business strategies building new alliances and expanding existing ones and pursuing new business initiatives that leverage coriums advanced transdermal technologies and product candidates    joe is joining corium at an important phase in the companys growth as we advance our portfolio of proprietary and partnered development programs said mr staple with his extensive experience in establishing highvalue partnering relationships joe will be assuming responsibility for business initiatives that leverage our capabilities and product assets and will contribute broadly to our future as a leader in developing firstinpatch products that can improve health outcomes and quality of life for patients this is an exciting time to join corium as i have the opportunity to work with an accomplished team in taking the company to the next level based on proven technology platforms a track record in transdermal innovation and proprietary pipeline assets said dr sarret i am looking forward to helping corium realize the potential of its technologies across small molecules biologics and vaccines and in pursuing new business opportunities for the companys proprietary programs  most recently dr sarret served as senior vice president strategic accounts at solazyme inc a publicly traded company focused on developing renewable products for a variety of industries and as chief executive officer and a member of the board of directors of sevident inc a startup biotechnology company developing medical diagnostics and life science research products  prior to joining solazyme dr sarret held positions of increasing responsibility from  to  at codexis inc a publicly traded international industrial biotechnology company including senior vice president and chief business officer and president pharmaceutical services and enzyme products  at codexis he was responsible for numerous strategic partnerships in the pharmaceutical and bioindustrial sectors including multiproduct development and supply agreements acquisitions and licensing transactions in addition dr sarret had pl responsibility for the companys global pharmaceutical ingredient manufacturing business unit which had annual sales of approximately  million previously he practiced corporate and transactional law at latham  watkins llp  dr sarret also served as attending physician and acting medical director for the hiv clinic at the university of california san francisco medical center  dr sarret holds a ba in human biology from stanford university an md from the university of california san francisco school of medicine and a jd from stanford law school and is a member of the phi beta kappa alpha omega alpha and order of the coif honor societies if you liked this article you might like  stocks under  making big moves toward big profits when a stock makes a largepercentage move it is often just the start of a new major trend  a trend that can lead to huge profits roberto pedone may    am edt wednesdays smallcap winners  losers corillian surges on a ashare sale to checkfree sarina penn feb    pm est wednesdays tech winners  losers daktronics plunges while spss catches a bid mark martinez feb    pm est checkfree to buy corillian the deal is valued at  million mark martinez feb    pm est trending jim cramer nails starbucks big decline warns again of downside to  amazon and general electric are fridays smoking hot tickers amzn tsla sbux ge aapl x  secrets tesla doesnt want to admit ahead of its big model  party us steel shares are being torched thanks to one stock analyst starbucks shares are crashing go out and buy advertising partners  thestreet inc all rights reservedaction alerts plus is a registered trademark of thestreet inc compare brokers joseph j sarret md jd executive profile  biography  bloomberg july    pm et pharmaceuticals company overview of corium international inc snapshotpeople  overviewboard memberscommittees executive profile joseph j sarret md jdchief business officer corium international incagetotal calculated compensationthis person is connected to  board members in  different organizations across  different industriesas of fiscal year  background dr joseph j sarret also known as joe md jd has been the chief business officer at corium international inc since april   dr sarret served as the chief business officer of codexis inc until august   and as its senior vice president from  to august   he served as senior vice president of strategic accounts at solazyme inc he served as the chief executive officer and director of sevident inc he served at codexis inc from   to  he served as the president of pharmaceutical services  enzyme products at codexis inc from october  to  he served as a senior vice president of corporate development at codexis inc since march  and served as its vice president of corporate development from april  to march  corporate counsel and director of business development since october   he was an associate at latham  watkins llp where he provided legal services to life sciences companies he also served as attending physician and later acting medical director for the hiv clinic at the university of california san francisco medical center dr sarret is a graduate of both the university of california san francisco school of medicine and stanford law school dr sarret holds a ba in human biology from stanford university an md from the university of california san francisco school of medicine and a jd from stanford law schoolread full background corporate headquarters  constitution drivemenlo park california united statesphone fax  board members memberships there is no board members memberships data available education ba stanford universityjd stanford university law schoolmd university of california san francisco school of medicine other affiliations stanford universitycodexis incstanford university law schooluniversity of california san francisco school of medicine annual compensation salarytotal annual compensation stocks options restricted stock awardsall other compensationexercisable optionsunexercisable optionstotal number of options total compensation total annual cash compensationtotal short term compensationother long term compensationtotal calculated compensation request profile update   the information and data displayed in this profile are created and managed by sp global market intelligence a division of sp global bloombergcom does not create or control the content for inquiries please contact sp global market intelligence directly by clicking here stock quotes market data is delayed at least  minutes company lookup competitor compensationnamepositioncompanycompensationvincent a forlenza chairman and chief executive officerbecton dickinson and companymheather bresch ceo  executive directormylan nvmshigetaka komori chairman group chief executive officer and executive officerfujifilm holdings corporationmhirotaka nakatomi chairman and chief executive officerhisamitsu pharmaceutical co incmstephen j farr phdcofounder chief executive officer president and directorzogenix inckcompensation as of fiscal year  sponsored financial commentaries sponsored links browse companies a b c d e f g h i j k l m n o p q r s t u v w x y z              request profile update only a company representative may request an update for the company profile documentation will be required to contact corium international inc please visit  company data is provided by sp global market intelligence please use this form to report any data issues information missing  please enter your information in the following fields company name your name your email address your phone number type of data overview executives key developments similar companies transactions update needed all data changes require verification from public sources please include the correct value or values and a source where we can verify cancel submit your requested update has been submitted our data partners will research the update request and update the information on this page if necessary research and followup could take several weeks if you have questions you can contact them at bwwebmasterbusinessweekcom close joseph j sarret md jd joins corium as chief business officer  pg  thestreet action alerts plus access aapjim cramers best stocks for charitable trust portfoliomost recent trade alert investing rules trading commandments real money access rm rules of investingjim cramers best stocks for  commandmentsstressed out stockscramers blog cramer mad money etfs futures markets much more banksbiotechretailtechpersonal financeretirementfinancial advisor centerhow to spendoptionsfixed incomevideo privacy policyterms of use  thestreet inc all rights reserved djia nasdaq sp  market data updated sign in your memberships your account account preferences alerts newsletters subscribe logout subscribe access insights and guidance from our wall street pros find the product thats right for you action alerts plus action alerts options daily swing trade income seeker quant ratings real money real money pro stocks under  top stocks trifecta stocks real money pro portfolio chairmans club compare all chatter on the street joseph j sarret md jd joins corium as chief business officer globenewswire apr    am edt about corium corium international inc is a commercialstage biopharmaceutical company focused on the development manufacture and commercialization of specialty pharmaceutical products that leverage the companys advanced transdermal and transmucosal delivery systems  corium has developed and is the sole commercial manufacturer of six prescription drug and consumer products with partners teva pharmaceuticals par pharmaceutical and procter  gamble  the company has two proprietary transdermal platforms corplex™ for small molecules and microcor ® a biodegradable microstructure technology for small molecules and biologics including vaccines peptides and proteins  the companys latestage pipeline includes a contraceptive patch codeveloped with agile therapeutics that is currently in phase  trials and additional transdermal products that are being codeveloped with teva  corium has multiple proprietary programs in preclinical and clinical development for the treatment of osteoporosis and neurological disorders for further information please visit wwwcoriumgroupcom forwardlooking statements this press release contains forwardlooking statements within the meaning of the us private securities litigation reform act of  including statements regarding our business strategy clinical trial plans and the advancement of our technologies and our proprietary and partnered products and product candidates forwardlooking statements are based on managements current expectations and projections and are subject to risks and uncertainties which may cause coriums actual results to differ materially from the statements contained herein further information on potential risk factors that could affect coriums business and its financial results are detailed in coriums quarterly report on form q for the quarter ended december   filed with the securities and exchange commission on february   and other reports as filed from time to time with the securities and exchange commission undue reliance should not be placed on forwardlooking statements especially guidance on future financial performance which speaks only as of the date they are made  corium undertakes no obligation to update publicly any forwardlooking statements to reflect new information events or circumstances after the date they were made or to reflect the occurrence of unanticipated events contact investor and media contact karen l bergman bcc partners kbergmanbccpartnerscom  if you liked this article you might like  stocks under  making big moves toward big profits when a stock makes a largepercentage move it is often just the start of a new major trend  a trend that can lead to huge profits roberto pedone may    am edt wednesdays smallcap winners  losers corillian surges on a ashare sale to checkfree sarina penn feb    pm est wednesdays tech winners  losers daktronics plunges while spss catches a bid mark martinez feb    pm est checkfree to buy corillian the deal is valued at  million mark martinez feb    pm est trending jim cramer nails starbucks big decline warns again of downside to   secrets tesla doesnt want to admit ahead of its big model  party starbucks shares are crashing go out and buy amazon and general electric are fridays smoking hot tickers amzn tsla sbux ge aapl x us steel shares are being torched thanks to one stock analyst advertising partners  thestreet inc all rights reservedaction alerts plus is a registered trademark of thestreet inc compare brokers microsoft personalized ad preferences to opt out of personalized ads in this browser your browser history must allow firstparty and thirdparty cookies and you must have your browsing experience set to not delete browsing history on exit instructions for enabling cookies and configuring your browsing history may be available in your browsers settings privacy or help documentation sign in hold on… we’re sorry but this didn’t work you can’t turn off personalized ads right now because your browser is currently blocking thirdparty cookies we can help you fix this issue let’s get started depending on what browser you use open options or settings make sure that thirdparty cookies are not blocked anymore to find out how search your browser’s help revisit httpchoicemicrosoftcomoptout and then on the “personalized ads in this browser” tile click off ext about our ads to create a more customized online experience some of the ads you may receive on microsoft websites and apps are tailored to your previous activities searches and site visits youre in control and heres where you can make the advertising choice thats right for you ext where can i learn more about advertising on microsoft websites and apps microsoft partners with oath appnexus and other third party service providers to help present customized content and display advertisements on msn outlookcom and other websites and apps microsoft also delivers search ads to bing and our search syndication partners learn more about microsoft’s privacy practices here you can learn more about interestbased ads from oath and appnexus in their privacy statements oath and appnexus what choices do i have about interestbased advertising on this page you can opt out of receiving interest based advertising from microsoft you can also opt out of receiving interestbased advertising from all selfregulatory members including microsoft oath appnexus and other third party ad networks at the following sites in the us digital advertising alliance daa in europe european interactive digital advertising alliance edaa in canada ad choices digital advertising alliance of canada daac you can control interestbased advertising in windows apps by turning off the advertising id in windows settings more choices do you want personalized ads from other companies questions if you have a privacy question or a question for the chief privacy officer of microsoft please contact us by using our web form we will respond to questions within  days ext personalized ads in this browser off optout is currently unavailable please try again later control the personalized ads setting for this web browser learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off ext personalized ads wherever i use my microsoft account off sign in to change optout is currently unavailable please try again later control the personalized ads setting that applies when you are signed in on any computer or device with your microsoft account including windows windows phone xbox and other devices learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off if you choose “generic” ads and use a browser your choice applies to everyone when using that browser as long as you do not clear your cookies ext personalized ads in windows in your windows settings you can turn off personalized ads that appear in apps on this device you’ll still see ads but they won’t be personalized anymore if you have windows  access the charms by touching or moving your pointer to the right edge of the screen click or tap settings and then click or tap change pc settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have windows  click or tap the start button click or tap settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have a windows mobile device go to settings tap on privacy tap on advertising id and then turn off let apps use my advertising id for experiences across apps if you want to turn off personalized ads from microsoft wherever you use your microsoft account including apps on windows windows phone xbox and other devices you can do so by selecting the microsoft account option above ext legal privacy  cookies   microsoft joseph j sarret m d j d joins corium international inc as chief business officer employer login post jobs job seeker login sign up search life sciences jobs search job title only radius miles km  news  news by subject  news by disease   news by date  search news get our freeindustry enewsletter email       joseph j sarret md jd joins corium international inc as chief business officer tweet   am menlo park calif april   globe newswire  corium international inc nasdaqcori a commercialstage biopharmaceutical company focused on the development manufacture and commercialization of specialty transdermal products today announced that joseph j sarret md jd has joined the company in the newly created position of chief business officer reporting to coriums president and chief executive officer peter d staple dr sarret will serve as a member of the companys executive leadership team with responsibility for developing and implementing coriums business strategies building new alliances and expanding existing ones and pursuing new business initiatives that leverage coriums advanced transdermal technologies and product candidates joe is joining corium at an important phase in the companys growth as we advance our portfolio of proprietary and partnered development programs said mr staple with his extensive experience in establishing highvalue partnering relationships joe will be assuming responsibility for business initiatives that leverage our capabilities and product assets and will contribute broadly to our future as a leader in developing firstinpatch products that can improve health outcomes and quality of life for patients this is an exciting time to join corium as i have the opportunity to work with an accomplished team in taking the company to the next level based on proven technology platforms a track record in transdermal innovation and proprietary pipeline assets said dr sarret i am looking forward to helping corium realize the potential of its technologies across small molecules biologics and vaccines and in pursuing new business opportunities for the companys proprietary programs most recently dr sarret served as senior vice president strategic accounts at solazyme inc a publicly traded company focused on developing renewable products for a variety of industries and as chief executive officer and a member of the board of directors of sevident inc a startup biotechnology company developing medical diagnostics and life science research products prior to joining solazyme dr sarret held positions of increasing responsibility from  to  at codexis inc a publicly traded international industrial biotechnology company including senior vice president and chief business officer and president pharmaceutical services and enzyme products at codexis he was responsible for numerous strategic partnerships in the pharmaceutical and bioindustrial sectors including multiproduct development and supply agreements acquisitions and licensing transactions in addition dr sarret had pl responsibility for the companys global pharmaceutical ingredient manufacturing business unit which had annual sales of approximately  million previously he practiced corporate and transactional law at latham  watkins llp dr sarret also served as attending physician and acting medical director for the hiv clinic at the university of california san francisco medical center dr sarret holds a ba in human biology from stanford university an md from the university of california san francisco school of medicine and a jd from stanford law school and is a member of the phi beta kappa alpha omega alpha and order of the coif honor societies about corium corium international inc is a commercialstage biopharmaceutical company focused on the development manufacture and commercialization of specialty pharmaceutical products that leverage the companys advanced transdermal and transmucosal delivery systems corium has developed and is the sole commercial manufacturer of six prescription drug and consumer products with partners teva pharmaceuticals par pharmaceutical and procter  gamble the company has two proprietary transdermal platforms corplex™ for small molecules and microcor® a biodegradable microstructure technology for small molecules and biologics including vaccines peptides and proteins the companys latestage pipeline includes a contraceptive patch codeveloped with agile therapeutics that is currently in phase  trials and additional transdermal products that are being codeveloped with teva corium has multiple proprietary programs in preclinical and clinical development for the treatment of osteoporosis and neurological disorders for further information please visit wwwcoriumgroupcom forwardlooking statements this press release contains forwardlooking statements within the meaning of the us private securities litigation reform act of  including statements regarding our business strategy clinical trial plans and the advancement of our technologies and our proprietary and partnered products and product candidates forwardlooking statements are based on managements current expectations and projections and are subject to risks and uncertainties which may cause coriums actual results to differ materially from the statements contained herein further information on potential risk factors that could affect coriums business and its financial results are detailed in coriums quarterly report on form q for the quarter ended december   filed with the securities and exchange commission on february   and other reports as filed from time to time with the securities and exchange commission undue reliance should not be placed on forwardlooking statements especially guidance on future financial performance which speaks only as of the date they are made corium undertakes no obligation to update publicly any forwardlooking statements to reflect new information events or circumstances after the date they were made or to reflect the occurrence of unanticipated events contact investor and media contact karen l bergman bcc partners kbergmanbccpartnerscom  help employers find you check out all the jobs and post your resume read at biospacecom related news corium international inc announces appointment of eric h bjerkholt to board of directors novartis ag nvs taps cancer guru to head boston rd group that specializes in immunooncology corium international inc reports first quarter fiscal  financial results ovascience ovas stock egged on by executive faith and strong pipeline corium international inc to report first quarter fiscal  financial results on tuesday february   harvard apparatus hart ceo resigns corium international inc to present at the th annual needham healthcare conference dr stephen farr appointed as ceo of zogenix zgnx to lead new strategic focus and advance latestage cns product pipeline corium international inc announces closing of expanded term loan facility with crg synta snta ceo steps down replacement named please enable javascript to view the comments powered by disqus comments powered by disqus • biospacecom • corium international inc   • biotechpharma  personnel                 joseph j sarret md jd joins corium as chief business officer  traders log in email password remember forgot password  become a member for free sign up sign up new membersign up for free new customerdiscover our portfolios united states united kingdom france deutschland schweiz de suisse fr settings dynamic quotes  offon markets equities north americaeuropeasiaoceaniamiddle east» more equities indexes dow jonessp nasdaq tsx compftse » more indexes currency  forex eur  usdgbp  usdusd  jpyusd  cadaud  usd» more currencies commodities goldcrude oil wticrude oil brentsilverplatinum» more commodities news latest news companiesmarketseconomycurrency  forexcommoditiesinterest ratesbusiness leadersfinancial calendareconomic calendar listed company analyst recorumorsiposcapital markets transactionsnew contractsprofits warningsappointmentspress releaseseventscorporate actions sector news energybasic materialsindustrialsconsumer cyclicalconsumer noncyclicalfinancialshealthcaretechnologytelecommunications servicesutilities analysis all analysiscommentariesindex analysisstock trading strategiescommodity analysisforex analysis stock picks all stock picks portfolios my portfolio virtual portfolios traders portfolios european portfoliousa portfolioasian portfolio screeners market screener homefundamental analyse top investor ratingtop trading ratingtop consensusgrowth stocksyield stockslow valuations technical analysis oversold stocksoverbought stocksclose to resistancesclose to supportsaccumulation phasemost volatile stocks watchlists my watchlists watchlists top lists yield stocksgrowth stocksundervalued stocks top  flop top news most read newshot news top fundamentals top capitalizationtop yieldtop pertop consensustop fundamentals top technicals top rsiunusual volumestop gapstop stim top movers top usatop canadatop uktop germanytop europetop asia tools market screenerdynamic chartfinancial calendareconomic calendarsector researchcurrency converter our services premium accessdiscover our services traders homepage    equities    nasdaq    corium international inc    cori corium international inc cori add to my list    mes dernières consultmost popular manage my lists  delayed     pm  usd     corium to report third quarter fiscal  financial results on t  corium presents clinical results from pilot bioequivalence study   corium internat  cori files an k departure of directors or certa summaryquoteschartsnewsanalysiscalendarcompanyfinancialsconsensusrevisions news summarymost relevantall newssector newstweets joseph j sarret md jd joins corium as chief business officer    pm cest send by mail  last name  name  from  to  you can enter multiple email addresses separated by commas message  required fields menlo park calif april   globe newswire  corium international inc nasdaqcori a commercialstage biopharmaceutical company focused on the development manufacture and commercialization of specialty transdermal products today announced that joseph j sarret md jd has joined the company in the newly created position of chief business officer reporting to coriums president and chief executive officer peter d staple dr sarret will serve as a member of the companys executive leadership team with responsibility for developing and implementing coriums business strategies building new alliances and expanding existing ones and pursuing new business initiatives that leverage coriums advanced transdermal technologies and product candidates    joe is joining corium at an important phase in the companys growth as we advance our portfolio of proprietary and partnered development programs said mr staple with his extensive experience in establishing highvalue partnering relationships joe will be assuming responsibility for business initiatives that leverage our capabilities and product assets and will contribute broadly to our future as a leader in developing firstinpatch products that can improve health outcomes and quality of life for patients this is an exciting time to join corium as i have the opportunity to work with an accomplished team in taking the company to the next level based on proven technology platforms a track record in transdermal innovation and proprietary pipeline assets said dr sarret i am looking forward to helping corium realize the potential of its technologies across small molecules biologics and vaccines and in pursuing new business opportunities for the companys proprietary programs  most recently dr sarret served as senior vice president strategic accounts at solazyme inc a publicly traded company focused on developing renewable products for a variety of industries and as chief executive officer and a member of the board of directors of sevident inc a startup biotechnology company developing medical diagnostics and life science research products  prior to joining solazyme dr sarret held positions of increasing responsibility from  to  at codexis inc a publicly traded international industrial biotechnology company including senior vice president and chief business officer and president pharmaceutical services and enzyme products  at codexis he was responsible for numerous strategic partnerships in the pharmaceutical and bioindustrial sectors including multiproduct development and supply agreements acquisitions and licensing transactions in addition dr sarret had pl responsibility for the companys global pharmaceutical ingredient manufacturing business unit which had annual sales of approximately  million previously he practiced corporate and transactional law at latham  watkins llp  dr sarret also served as attending physician and acting medical director for the hiv clinic at the university of california san francisco medical center  dr sarret holds a ba in human biology from stanford university an md from the university of california san francisco school of medicine and a jd from stanford law school and is a member of the phi beta kappa alpha omega alpha and order of the coif honor societies about corium corium international inc is a commercialstage biopharmaceutical company focused on the development manufacture and commercialization of specialty pharmaceutical products that leverage the companys advanced transdermal and transmucosal delivery systems  corium has developed and is the sole commercial manufacturer of six prescription drug and consumer products with partners teva pharmaceuticals par pharmaceutical and procter  gamble  the company has two proprietary transdermal platforms corplex™ for small molecules and microcor® a biodegradable microstructure technology for small molecules and biologics including vaccines peptides and proteins  the companys latestage pipeline includes a contraceptive patch codeveloped with agile therapeutics that is currently in phase  trials and additional transdermal products that are being codeveloped with teva  corium has multiple proprietary programs in preclinical and clinical development for the treatment of osteoporosis and neurological disorders for further information please visit wwwcoriumgroupcom forwardlooking statements this press release contains forwardlooking statements within the meaning of the us private securities litigation reform act of  including statements regarding our business strategy clinical trial plans and the advancement of our technologies and our proprietary and partnered products and product candidates forwardlooking statements are based on managements current expectations and projections and are subject to risks and uncertainties which may cause coriums actual results to differ materially from the statements contained herein further information on potential risk factors that could affect coriums business and its financial results are detailed in coriums quarterly report on form q for the quarter ended december   filed with the securities and exchange commission on february   and other reports as filed from time to time with the securities and exchange commission undue reliance should not be placed on forwardlooking statements especially guidance on future financial performance which speaks only as of the date they are made  corium undertakes no obligation to update publicly any forwardlooking statements to reflect new information events or circumstances after the date they were made or to reflect the occurrence of unanticipated events contact investor and media contact karen l bergman bcc partners kbergmanbccpartnerscom   globenewswire   latest news on corium international inc  corium to report third quarter fiscal  financial results on thursday aug  corium presents clinical results from pilot bioequivalence study of corplext  corium internationalinc nasdaq  cori files an k departure of directors or  corium international inc  change in directors or principal officers form k  corium international  patent issued for method and device for transdermal deliv  corium to present clinical results from pilot bioequivalence study of oncewe  corium joins russell ® index  corium international  to present at the jefferies  global healthcare confer  corium to present at the jefferies  global healthcare conference   corium international  announces closing of followon offering of common stock a more news news from seekingalpha  daily insider ratings round up   aldeyra corium sigma designs zogenix   midday gainers  losers  corium international  room to run  insiderinsightscom daily round up   praa sumr iff smrt sanw lsxma lsxmk  healthcare  top  gainers  losers   am financials  sales   m ebit   m net income   m debt   yield   pe ratio   pe ratio  capi  sales  x capi  sales  x capitalization  m more financials chart corium international inc duration  auto  months  months  months  months  year  years  years  years max period  day week fullscreen chart technical analysis trends corium international inc short termmidtermlong termtrendsbullishbullishbullish technical analysis income statement evolution please enable javascript in your browsers settings to use dynamic charts more financials consensus sell buy mean consensus outperform number of analysts  average target price   spread  average target  consensus details eps revisions please enable javascript in your browsers settings to use dynamic charts more estimates revisions managers nametitlepeter d staple president chief executive officer  director david l greenwood executive chairman robert s breuil chief financial officer parminder singh cto vice presidentresearch  development ron welcome eastman independent nonexecutive director more about the company sector and competitors st jancapitalization m corium international inc johnson  johnson  novartis  roche holding ltd  pfizer  merck and company  more results traderscom marketsnewsanalysisstock picksportfoliosscreenerswatchliststop  floptoolsour servicesabout surperformance sascontact usadvertiselegal informationsabout usstay connected facebooktwitterpartners börse aktien kurse und nachrichtenbest tweets copyright   surperformance all rights reserved slave joseph j sarret md jd joins corium as chief business officer nasdaqcori facebook google linkedin twitter email rss apr   previous release  next release pdf joseph j sarret md jd joins corium as chief business officer menlo park calif april   globe newswire  corium international inc nasdaqcori a commercialstage biopharmaceutical company focused on the development manufacture and commercialization of specialty transdermal products today announced that joseph j sarret md jd has joined the company in the newly created position of chief business officer reporting to coriums president and chief executive officer peter d staple dr sarret will serve as a member of the companys executive leadership team with responsibility for developing and implementing coriums business strategies building new alliances and expanding existing ones and pursuing new business initiatives that leverage coriums advanced transdermal technologies and product candidates    joe is joining corium at an important phase in the companys growth as we advance our portfolio of proprietary and partnered development programs said mr staple with his extensive experience in establishing highvalue partnering relationships joe will be assuming responsibility for business initiatives that leverage our capabilities and product assets and will contribute broadly to our future as a leader in developing firstinpatch products that can improve health outcomes and quality of life for patients this is an exciting time to join corium as i have the opportunity to work with an accomplished team in taking the company to the next level based on proven technology platforms a track record in transdermal innovation and proprietary pipeline assets said dr sarret i am looking forward to helping corium realize the potential of its technologies across small molecules biologics and vaccines and in pursuing new business opportunities for the companys proprietary programs  most recently dr sarret served as senior vice president strategic accounts at solazyme inc a publicly traded company focused on developing renewable products for a variety of industries and as chief executive officer and a member of the board of directors of sevident inc a startup biotechnology company developing medical diagnostics and life science research products  prior to joining solazyme dr sarret held positions of increasing responsibility from  to  at codexis inc a publicly traded international industrial biotechnology company including senior vice president and chief business officer and president pharmaceutical services and enzyme products  at codexis he was responsible for numerous strategic partnerships in the pharmaceutical and bioindustrial sectors including multiproduct development and supply agreements acquisitions and licensing transactions in addition dr sarret had pl responsibility for the companys global pharmaceutical ingredient manufacturing business unit which had annual sales of approximately  million previously he practiced corporate and transactional law at latham  watkins llp  dr sarret also served as attending physician and acting medical director for the hiv clinic at the university of california san francisco medical center  dr sarret holds a ba in human biology from stanford university an md from the university of california san francisco school of medicine and a jd from stanford law school and is a member of the phi beta kappa alpha omega alpha and order of the coif honor societiesabout corium corium international inc is a commercialstage biopharmaceutical company focused on the development manufacture and commercialization of specialty pharmaceutical products that leverage the companys advanced transdermal and transmucosal delivery systems  corium has developed and is the sole commercial manufacturer of six prescription drug and consumer products with partners teva pharmaceuticals par pharmaceutical and procter  gamble  the company has two proprietary transdermal platforms corplex™ for small molecules and microcor® a biodegradable microstructure technology for small molecules and biologics including vaccines peptides and proteins  the companys latestage pipeline includes a contraceptive patch codeveloped with agile therapeutics that is currently in phase  trials and additional transdermal products that are being codeveloped with teva  corium has multiple proprietary programs in preclinical and clinical development for the treatment of osteoporosis and neurological disorders for further information please visit wwwcoriumgroupcomforwardlooking statements this press release contains forwardlooking statements within the meaning of the us private securities litigation reform act of  including statements regarding our business strategy clinical trial plans and the advancement of our technologies and our proprietary and partnered products and product candidates forwardlooking statements are based on managements current expectations and projections and are subject to risks and uncertainties which may cause coriums actual results to differ materially from the statements contained herein further information on potential risk factors that could affect coriums business and its financial results are detailed in coriums quarterly report on form q for the quarter ended december   filed with the securities and exchange commission on february   and other reports as filed from time to time with the securities and exchange commission undue reliance should not be placed on forwardlooking statements especially guidance on future financial performance which speaks only as of the date they are made  corium undertakes no obligation to update publicly any forwardlooking statements to reflect new information events or circumstances after the date they were made or to reflect the occurrence of unanticipated eventscontact investor and media contact karen l bergman bcc partners kbergmanbccpartnerscom  joseph j sarret md jd joins corium as chief business officer  firstword medtech login  subscribe friday july   get unlimited medtech plus subscriptions for one low fixed rate with a firstword medtech country licenseclick here for more details home my newsall my news my companywatch my conditionwatch my marketsegmentwatch my medicalmeetingwatch my productwatch my regulatorywatch all newsexplore latest news all company news all condition news all medical meeting news all product news all market segment news all regulatory market and agency news all therapeutic category news most popularmost popular in the last  hours most popular in the last  days most popular in the last  days storywatchduodenoscope reprocessing in focus emerging markets latest earnings reports pharma alliances product approvals and certifications us vaginalmesh product lawsuits where health meets tech servicesmobile search twitter rss podcasts radio joseph j sarret md jd joins corium as chief business officer ref globenewswire april th  tags corporate affairs drug delivery agile therapeutics alpha omega corium par pharmaceutical teva tweet email print menlo park calif april   globe newswire  corium international inc nasdaqcori a commercialstage biopharmaceutical company focused on the development manufacture and commercialization of specialty transdermal products today announced that joseph j sarret md jd has joined the company in the newly created position of chief business officer reporting to coriums president and chief executive officer peter d staple dr sarret will serve as a member of the companys executive leadership team with responsibility for developing and implementing coriums business strategies building new alliances and expanding existing ones and pursuing new business initiatives that leverage coriums advanced transdermal technologies and product candidates    joe is joining corium at an important phase in the companys growth as we advance our portfolio of proprietary and partnered development programs said mr staple with his extensive experience in establishing highvalue partnering relationships joe will be assuming responsibility for business initiatives that leverage our capabilities and product assets and will contribute broadly to our future as a leader in developing firstinpatch products that can improve health outcomes and quality of life for patients this is an exciting time to join corium as i have the opportunity to work with an accomplished team in taking the company to the next level based on proven technology platforms a track record in transdermal innovation and proprietary pipeline assets said dr sarret i am looking forward to helping corium realize the potential of its technologies across small molecules biologics and vaccines and in pursuing new business opportunities for the companys proprietary programs  most recently dr sarret served as senior vice president strategic accounts at solazyme inc a publicly traded company focused on developing renewable products for a variety of industries and as chief executive officer and a member of the board of directors of sevident inc a startup biotechnology company developing medical diagnostics and life science research products  prior to joining solazyme dr sarret held positions of increasing responsibility from  to  at codexis inc a publicly traded international industrial biotechnology company including senior vice president and chief business officer and president pharmaceutical services and enzyme products  at codexis he was responsible for numerous strategic partnerships in the pharmaceutical and bioindustrial sectors including multiproduct development and supply agreements acquisitions and licensing transactions in addition dr sarret had pl responsibility for the companys global pharmaceutical ingredient manufacturing business unit which had annual sales of approximately  million previously he practiced corporate and transactional law at latham  watkins llp  dr sarret also served as attending physician and acting medical director for the hiv clinic at the university of california san francisco medical center  dr sarret holds a ba in human biology from stanford university an md from the university of california san francisco school of medicine and a jd from stanford law school and is a member of the phi beta kappa alpha omega alpha and order of the coif honor societies about corium corium international inc is a commercialstage biopharmaceutical company focused on the development manufacture and commercialization of specialty pharmaceutical products that leverage the companys advanced transdermal and transmucosal delivery systems  corium has developed and is the sole commercial manufacturer of six prescription drug and consumer products with partners teva pharmaceuticals par pharmaceutical and procter  gamble  the company has two proprietary transdermal platforms corplex™ for small molecules and microcor® a biodegradable microstructure technology for small molecules and biologics including vaccines peptides and proteins  the companys latestage pipeline includes a contraceptive patch codeveloped with agile therapeutics that is currently in phase  trials and additional transdermal products that are being codeveloped with teva  corium has multiple proprietary programs in preclinical and clinical development for the treatment of osteoporosis and neurological disorders for further information please visit wwwcoriumgroupcom forwardlooking statements this press release contains forwardlooking statements within the meaning of the us private securities litigation reform act of  including statements regarding our business strategy clinical trial plans and the advancement of our technologies and our proprietary and partnered products and product candidates forwardlooking statements are based on managements current expectations and projections and are subject to risks and uncertainties which may cause coriums actual results to differ materially from the statements contained herein further information on potential risk factors that could affect coriums business and its financial results are detailed in coriums quarterly report on form q for the quarter ended december   filed with the securities and exchange commission on february   and other reports as filed from time to time with the securities and exchange commission undue reliance should not be placed on forwardlooking statements especially guidance on future financial performance which speaks only as of the date they are made  corium undertakes no obligation to update publicly any forwardlooking statements to reflect new information events or circumstances after the date they were made or to reflect the occurrence of unanticipated events investor and media contact karen l bergman bcc partners  did you like this article share this article twitter facebook google digg email print   related newscorium reports first quarter fiscal  financial resultscorium reports fourth quarter and fiscal year  financial results and yearend highlightscorium announces issuance of us patent for microcor transdermal system for a broad range of therapeutics and vaccinesindustry veteran jessica rousset joins cure pharmaceutical as chief business officerinvivo therapeutics names tamara l joseph as its general counsel and chief compliance officer reference articlesjoseph j sarret md jd joins corium as chief business officer  globenewswire recent reports effective sales and marketing strategies for drugs with companion diagnostics ref firstword dossierpatientcentricity solving the latest pharma puzzle ref firstword dossierbiosimilar defensive plays – assessing the options ref firstword dossier about firstword medtech  refer a colleague  upgrade your firstword medtech  contact firstword medtech  firstword reportsadvertise with firstword medtech  industry partner showcaseall contents copyright   doctors guide publishing limited all rights reservedterms of use  privacy policy